Figures & data
Table 1 Patient demographics and clinical characteristics by GLP1 RA status (global)
Table 2 Patient demographics and clinical characteristics by region
Figure 1 Patient-survey cohort (n=2,173).
Notes: Bases for each analysis differ based on the number of responses for question.
Abbreviations: GLP1 RA, glucagon-like peptide-1 receptor agonist; T2DM, type 2 diabetes mellitus.
Abbreviations: GLP1 RA, glucagon-like peptide-1 receptor agonist; T2DM, type 2 diabetes mellitus.
Figure 2 Reasons for GLP1 RA discontinuation in the past 6 months, ranked by frequency.
Notes: (A) Physicians (n=443); (B) patients (n=194).
Abbreviations: GI, gastrointestinal; GLP1 RA, glucagon-like peptide-1 receptor agonist.
Abbreviations: GI, gastrointestinal; GLP1 RA, glucagon-like peptide-1 receptor agonist.
Figure 3 Problems reported with GLP1 RA treatment.
Notes: *GI-related issues. Physician-estimated versus patient-reported prevalence of each problem among patients currently using GLP1 RAs. (A) Global results; (B) EU5 results (France, Germany, Italy, Spain, and the UK); (C) US results; (D) global results, proportion of patients reporting problems as very or extremely bothersome. Exact questions listed in Table S1.
Abbreviations: GI, gastrointestinal; GLP1 RA, glucagon-like peptide-1 receptor agonist.
Abbreviations: GI, gastrointestinal; GLP1 RA, glucagon-like peptide-1 receptor agonist.
